Investors
Listed on Euronext Brussels

BuildingEurope's leadingfull-service CRO group.

Through a focused buy-and-build strategy, Oxurion is consolidating high-value clinical research organizations and clinical technology across Europe.

7,000+
Patient files processed across 12+ countries
20+
Active academic, biotech & pharma partners
Featured acquisition · 72% stake

Powered byAxiodis,biometrics expert.

A French CRO specialized in biometrics, clinical data management and biostatistics — running its proprietary Exagis eCRF platform across complex studies.

15yrs
Of regulatory-grade biometrics expertise
12+
European countries served end-to-end
Proprietary technology

Exagis,a next-geneCRF & data system.

Purpose-built for biometrics and clinical data workflows. AI-assisted validation and virtual patient technologies on the roadmap.

AI
Intelligent data validation roadmap
EU-wide
Scalable across Europe's regulatory frameworks
MissionOxurion NV · Leuven, Belgium

Accelerating clinical research across Europe.

SAMPLE 247-Bphase iib · 04/26
CRO platformHeadquartered in Leuven

Our Mission

Oxurion (Euronext Brussels: OXUR) is a Belgian company building a leading group of clinical research organizations in Europe. By acquiring and integrating specialist CROs across the full clinical research value chain — from study design, regulatory affairs and clinical operations to data management, biostatistics, medical writing, pharmacovigilance, real-world evidence and market access — Oxurion creates an end-to-end platform supporting drug and device development from early phases to post-approval.

Our Commitment

We are committed to building a resilient, multi-company CRO platform that integrates clinical development, evidence generation and market access — supporting faster, smarter and higher-quality decision-making across the product lifecycle.

Discover who we are
Platform View full strategy

Building a European clinical data platform.

Oxurion is a Euronext Brussels-listed company focused on building a next-generation European platform dedicated to clinical data, biometrics and AI-driven clinical research services. Through a targeted buy-and-build strategy, we consolidate high-value CRO and clinical technology capabilities.

01 · ANCHOR ACQUISITION

72% controlling stake in Axiodis CRO

A French specialist in clinical biometrics and data management — the cornerstone of the Oxurion buy-and-build platform.

Learn more about Axiodis
02 · TECHNOLOGY

Exagis — next-gen eCRF & data system

Proprietary platform purpose-built for biometrics and clinical data management workflows.

Discover Exagis
03 · SCALE
7,000+

Patient files processed across 12+ European countries.

04 · NETWORK
20+

Active partners: academic, biotech & pharma.

05 · EXPERTISE

Full clinical data expertise

Biometrics, data management, statistical analysis and regulatory-ready clinical data.

06 · ROADMAP

AI integration

Intelligent data validation and virtual patient technologies on the active roadmap.

07 · STRATEGY

Active acquisition pipeline

Targeting complementary CRO and clinical data businesses across Europe.

08 · SCALABILITY

Hybrid CRO + software

Combining operational CRO services with proprietary software and AI capabilities.

Featured acquisition · 72%

Axiodis CRO

Axiodis is a French clinical research organization specialized in biometrics, clinical data management and biostatistics. Through its proprietary Exagis platform and regulatory expertise, Axiodis supports biotech, pharmaceutical, medtech and academic sponsors in the execution of complex clinical studies.

Oxurion's ambition is to build a leading European clinical data ecosystem combining technology, regulatory expertise and operational excellence to accelerate the development of next-generation therapies.
BiometricsData MgmtBiostatsRegulatoryExagis eCRFAAXIODIS
What's newView all news

Read the latest investor news.

GENERAL2 Jun 2026

Oxurion expands its capabilities to address the growing demand for GLP-1 and peptide clinical research services

REGULATED2 Jun 2026

Oxurion – Termination of discussions for the French CRO project (LOI dated 13/10/25) and prioritization of the international target (LOI dated 19/03/26)